Browse drugs

…ths after rituximabConclusions In patients with thrombotic APS, rituximab treatment may prevent thrombotic recurrence with a significant …

…ies rendering it capable of superior B-cell killing compared to rituximab.5 The NOBILITY trial, a phase 2 clinical trial in patients with…

…ow (see section on Current treatments). The antifibrotic drugs, pirfenidone and nintedanib, are established treatments for idiopathic pulmo…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…mean current age of 45.3 years. Biologic therapies consisted of Belimumab in 47 patients (56.0%), Anifrolumab in 26 (31.0%), and Rituxima…

…M, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results fro…

…ive analysis of 210 SLE patients treated between 2000-2022 with rituximab. Super-responders were defined by: (1) at least 3 years of foll…

…endent clinical trials: BEAT-lupus and CALIBRATE both comparing belimumab after rituximab vs. rituximab. We further evaluated its potenti…

…t to standard anticoagulant therapy and requires treatment with rituximab with good effect.…

… refractory to multiple therapies, highlighting the response to rituximab. Prior reports support the benefit of rituximab in SLE-associat…

…ater cumulative time in LLDAS over 12 months is achieved in the rituximab group compared with placebo. We will also evaluate secondary ou…

…ed blood cell destruction and underlying autoimmunity. While on hydroxychloroquine, she required chronic glucocorticoid therapy (7.5–15 mg/day) to…